Literature DB >> 15365926

Intrathecal morphine for off-pump coronary artery bypass grafting.

Samuel Metz1, Nanette Schwann, Wael Hassanein, Brian Yuskevich, Todd Nixon.   

Abstract

OBJECTIVE: To determine if preinduction intrathecal morphine is associated with successful intraoperative extubation in patients undergoing off-pump coronary artery bypass grafting.
DESIGN: A retrospective noncontrolled chart review of all patients undergoing off-pump coronary artery bypass grafting.
SETTING: Single university hospital. PARTICIPANTS: One hundred twelve patients.
INTERVENTIONS: One hundred twelve of 150 patients received preinduction intrathecal morphine as part of routine anesthetic care for off-pump coronary artery bypass grafting. Patients received a mean of 1.0 mg of intrathecal morphine (range 0.3-1.6 mg); average weight-corrected dose was 13.2 microg/kg (range 5-24 microg/kg).
MEASUREMENTS AND MAIN RESULTS: This study included intraoperative extubation rate, delayed respiratory depression, and other complications potentially attributable to intrathecal morphine. An intraoperative extubation rate of 77% was found. Five patients received naloxone postoperatively, 4 of them for delayed respiratory depression.
CONCLUSIONS: It is concluded that intrathecal morphine is associated with a high intraoperative extubation rate in patients undergoing off-pump coronary artery bypass grafting. The authors' practice included 24-hour respiratory monitoring to detect delayed respiratory depression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365926     DOI: 10.1053/j.jvca.2004.05.023

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  1 in total

1.  Intrathecal morphine plus general anesthesia in cardiac surgery: effects on pulmonary function, postoperative analgesia, and plasma morphine concentration.

Authors:  Luciana Moraes dos Santos; Verônica Cavani Jorge Santos; Silvia Regina Cavani Jorge Santos; Luiz Marcelo Sá Malbouisson; Maria José Carvalho Carmona
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.